Notice Information
Notice Title
Molecular Screening Services
Notice Description
This Prior Information Notice (PIN) is a call for competition and is separate to any tender opportunity. Its purpose is to inform the market of an up-and-coming tender opportunity. NHSBT are looking for a fully integrated high throughput testing solution for an automated Nucleic Acid Amplification Testing (NAT) system which can detect HBV DNA, HIV-1 RNA, HIV-2 RNA, HCV RNA, HEV RNA in EDTA plasma from blood and non-blood (e.g. stem cell, tissue) donors including from deceased (non-heart beating) donors. The solution must have the relevant CE/UKCA marking to support this ability. <br/>Organisations who express an interest must declare this by 17th April 2023 including a statement confirming their current participation in a Kit Evaluation Group (KEG) evaluation, or their intention to join the KEG process, or confirmation that their testing solution has previously been KEG approved. Any organisations wishing to participate in the KEG evaluation process must also submit their relevant assay Instructions For Use (IFU) by 17th April 2023 to tennille.madigan@nhsbt.nhs.uk<br/><br/>Organisations who express an interest to participate will be invite to future engagement sessions in March/April 2023.
Lot Information
Lot 1
NHSBT requires a direct contractual relationship with either the manufacturer or any other economic operator for a complete end-to-end integrated solution, which must include all the necessary equipment, installation, maintenance, consumables, reagents, software, including an inter-operability provision with NHSBT's existing IT infrastructure, and an overall on-going support mechanism that may be required to carry out the necessary testing as stated below.
All in vitro diagnostic medical devices, for example, instruments, consumables, and reagents must be CE/UKCA marked for specifically cadaveric donors.
Great Britain (GB) will continue to recognise CE marking under the IVDD or IVDR until 30 June 2024 and from 1 July 2024 devices placed on the GB market must be UKCA marked under the UK MDR 2002 as amended. The end-to-end solution must be capable of producing test results in a format that can be utilised by NHSBT's host IT system. NHSBT are looking for a fully integrated, high throughput, automated Nucleic Acid Amplification Testing (NAT) screening system which can detect HBV DNA, HIV-1 RNA, HIV-2 RNA, HCV RNA, HEV RNA in EDTA plasma samples from blood and non-blood (e.g. stem cell, tissue) donors including samples from deceased (non-heart beating) donors, as individual donations i.e.: not pooled
Molecular Screening will be performed by NHSBTs Microbiology Services Laboratory in Colindale (London) with the following approximate number of samples (based on historical actual tests) per marker per year for both donation screening and confirmatory testing:
* HBV DNA: 7,381 screening tests as part of a multiplex & 1,082 individual tests for confirmatory testing
* HIV-1/HIV-2 RNA: 7,381 screening tests as part of a multiplex & 652 individual tests for confirmatory testing
* HCV RNA: 7,381 screening tests as part of a multiplex & 640 individual tests for confirmatory testing
* HEV RNA: 7,126 individual tests for either screening or confirmatory testing
* Pooling is not required, all samples will be tested as an individual donation.
It is important that interested parties respond to this PIN, as prior KEG approval will be a mandatory requirement for any associated future tender opportunity, in-line with the requirements of the Guidelines for the Blood Transfusion Services in the United Kingdom (Red Book - https://www.transfusionguidelines.org/red-book). NHSBT will seek to understand the status of assays which would be offered with regards to KEG. Any organisations wishing to participate in the KEG evaluation process must also submit their relating assay IFUs by 17th April 2023 to tennille.madigan@nhsbt.nhs.uk
Further details on KEG and the process will be provided during Supplier Engagement. The format of Supplier Engagement will be communicated to those organisations that respond to this PIN; however, this is likely to be virtual meetings conducted via Microsoft Teams during March/April 2023. Expressions of interest should be e-mailed to tennille.madigan@nhsbt.nhs.uk by 17th April 2023.
Notice Details
Publication & Lifecycle
- Open Contracting ID
- ocds-h6vhtk-03b3e2
- Publication Source
- Find A Tender Service
- Latest Notice
- https://www.find-tender.service.gov.uk/Notice/007841-2023
- Current Stage
- Planning
- All Stages
- Planning
Procurement Classification
- Notice Type
- Planning Notice
- Procurement Type
- Standard
- Procurement Category
- Goods
- Procurement Method
- Not Specified
- Procurement Method Details
- Not specified
- Tender Suitability
- Not specified
- Awardee Scale
- Not specified
Common Procurement Vocabulary (CPV)
- CPV Divisions
33 - Medical equipments, pharmaceuticals and personal care products
48 - Software package and information systems
71 - Architectural, construction, engineering and inspection services
-
- CPV Codes
33000000 - Medical equipments, pharmaceuticals and personal care products
33124000 - Diagnostics and radiodiagnostic devices and supplies
33124110 - Diagnostic systems
33124130 - Diagnostic supplies
33127000 - Immuno-analysis devices
33140000 - Medical consumables
33141625 - Diagnostic kits
33696200 - Blood-testing reagents
33696500 - Laboratory reagents
48921000 - Automation system
71900000 - Laboratory services
Notice Value(s)
- Tender Value
- £3,800,000 £1M-£10M
- Lots Value
- Not specified
- Awards Value
- Not specified
- Contracts Value
- Not specified
Notice Dates
- Publication Date
- 17 Mar 20232 years ago
- Submission Deadline
- Not specified
- Future Notice Date
- 3 May 2023Expired
- Award Date
- Not specified
- Contract Period
- Not specified - Not specified
- Recurrence
- Not specified
Notice Status
- Tender Status
- Planned
- Lots Status
- Planned
- Awards Status
- Not Specified
- Contracts Status
- Not Specified
Buyer & Supplier
Contracting Authority (Buyer)
- Main Buyer
- NHS BLOOD AND TRANSPLANT
- Contact Name
- Tennille Madigan
- Contact Email
- tennille.madigan@nhsbt.nhs.uk
- Contact Phone
- +44 7795483583
Buyer Location
- Locality
- BRISTOL
- Postcode
- BS34 7QH
- Post Town
- Bristol
- Country
- England
-
- Major Region (ITL 1)
- TLK South West (England)
- Basic Region (ITL 2)
- TLK5 West of England
- Small Region (ITL 3)
- TLK52 Bath & North East Somerset and South Gloucestershire
- Delivery Location
- Not specified
-
- Local Authority
- South Gloucestershire
- Electoral Ward
- Filton
- Westminster Constituency
- Filton and Bradley Stoke
Further Information
Open Contracting Data Standard (OCDS)
View full OCDS Record for this contracting process
The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.
{
"tag": [
"compiled"
],
"id": "ocds-h6vhtk-03b3e2-2023-03-17T13:31:55Z",
"date": "2023-03-17T13:31:55Z",
"ocid": "ocds-h6vhtk-03b3e2",
"initiationType": "tender",
"tender": {
"id": "ocds-h6vhtk-03b3e2",
"legalBasis": {
"id": "32014L0024",
"scheme": "CELEX"
},
"title": "Molecular Screening Services",
"status": "planned",
"classification": {
"scheme": "CPV",
"id": "33124130",
"description": "Diagnostic supplies"
},
"mainProcurementCategory": "goods",
"description": "This Prior Information Notice (PIN) is a call for competition and is separate to any tender opportunity. Its purpose is to inform the market of an up-and-coming tender opportunity. NHSBT are looking for a fully integrated high throughput testing solution for an automated Nucleic Acid Amplification Testing (NAT) system which can detect HBV DNA, HIV-1 RNA, HIV-2 RNA, HCV RNA, HEV RNA in EDTA plasma from blood and non-blood (e.g. stem cell, tissue) donors including from deceased (non-heart beating) donors. The solution must have the relevant CE/UKCA marking to support this ability. <br/>Organisations who express an interest must declare this by 17th April 2023 including a statement confirming their current participation in a Kit Evaluation Group (KEG) evaluation, or their intention to join the KEG process, or confirmation that their testing solution has previously been KEG approved. Any organisations wishing to participate in the KEG evaluation process must also submit their relevant assay Instructions For Use (IFU) by 17th April 2023 to tennille.madigan@nhsbt.nhs.uk<br/><br/>Organisations who express an interest to participate will be invite to future engagement sessions in March/April 2023.",
"value": {
"amount": 3800000,
"currency": "GBP"
},
"lots": [
{
"id": "1",
"description": "NHSBT requires a direct contractual relationship with either the manufacturer or any other economic operator for a complete end-to-end integrated solution, which must include all the necessary equipment, installation, maintenance, consumables, reagents, software, including an inter-operability provision with NHSBT's existing IT infrastructure, and an overall on-going support mechanism that may be required to carry out the necessary testing as stated below. <br/>All in vitro diagnostic medical devices, for example, instruments, consumables, and reagents must be CE/UKCA marked for specifically cadaveric donors. <br/>Great Britain (GB) will continue to recognise CE marking under the IVDD or IVDR until 30 June 2024 and from 1 July 2024 devices placed on the GB market must be UKCA marked under the UK MDR 2002 as amended. The end-to-end solution must be capable of producing test results in a format that can be utilised by NHSBT's host IT system. NHSBT are looking for a fully integrated, high throughput, automated Nucleic Acid Amplification Testing (NAT) screening system which can detect HBV DNA, HIV-1 RNA, HIV-2 RNA, HCV RNA, HEV RNA in EDTA plasma samples from blood and non-blood (e.g. stem cell, tissue) donors including samples from deceased (non-heart beating) donors, as individual donations i.e.: not pooled<br/>Molecular Screening will be performed by NHSBTs Microbiology Services Laboratory in Colindale (London) with the following approximate number of samples (based on historical actual tests) per marker per year for both donation screening and confirmatory testing: <br/>* HBV DNA: 7,381 screening tests as part of a multiplex & 1,082 individual tests for confirmatory testing<br/>* HIV-1/HIV-2 RNA: 7,381 screening tests as part of a multiplex & 652 individual tests for confirmatory testing<br/>* HCV RNA: 7,381 screening tests as part of a multiplex & 640 individual tests for confirmatory testing<br/>* HEV RNA: 7,126 individual tests for either screening or confirmatory testing<br/>* Pooling is not required, all samples will be tested as an individual donation.<br/><br/><br/>It is important that interested parties respond to this PIN, as prior KEG approval will be a mandatory requirement for any associated future tender opportunity, in-line with the requirements of the Guidelines for the Blood Transfusion Services in the United Kingdom (Red Book - https://www.transfusionguidelines.org/red-book). NHSBT will seek to understand the status of assays which would be offered with regards to KEG. Any organisations wishing to participate in the KEG evaluation process must also submit their relating assay IFUs by 17th April 2023 to tennille.madigan@nhsbt.nhs.uk <br/>Further details on KEG and the process will be provided during Supplier Engagement. The format of Supplier Engagement will be communicated to those organisations that respond to this PIN; however, this is likely to be virtual meetings conducted via Microsoft Teams during March/April 2023. Expressions of interest should be e-mailed to tennille.madigan@nhsbt.nhs.uk by 17th April 2023.",
"status": "planned"
}
],
"items": [
{
"id": "1",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "71900000",
"description": "Laboratory services"
},
{
"scheme": "CPV",
"id": "48921000",
"description": "Automation system"
},
{
"scheme": "CPV",
"id": "33696500",
"description": "Laboratory reagents"
},
{
"scheme": "CPV",
"id": "33141625",
"description": "Diagnostic kits"
},
{
"scheme": "CPV",
"id": "33124110",
"description": "Diagnostic systems"
},
{
"scheme": "CPV",
"id": "33140000",
"description": "Medical consumables"
},
{
"scheme": "CPV",
"id": "33124000",
"description": "Diagnostics and radiodiagnostic devices and supplies"
},
{
"scheme": "CPV",
"id": "33696200",
"description": "Blood-testing reagents"
},
{
"scheme": "CPV",
"id": "33127000",
"description": "Immuno-analysis devices"
},
{
"scheme": "CPV",
"id": "33000000",
"description": "Medical equipments, pharmaceuticals and personal care products"
}
],
"deliveryAddresses": [
{
"region": "UK"
}
],
"deliveryLocation": {
"description": "Colindale"
},
"relatedLot": "1"
}
],
"communication": {
"futureNoticeDate": "2023-05-04T00:00:00+01:00",
"atypicalToolUrl": "https://health-family.force.com/s/Welcome"
}
},
"parties": [
{
"id": "GB-FTS-18293",
"name": "NHS Blood and Transplant",
"identifier": {
"legalName": "NHS Blood and Transplant"
},
"address": {
"streetAddress": "500 North Bristol Park",
"locality": "Bristol",
"region": "UKK11",
"postalCode": "BS34 7QH",
"countryName": "United Kingdom"
},
"contactPoint": {
"name": "Tennille Madigan",
"telephone": "+44 7795483583",
"email": "tennille.madigan@nhsbt.nhs.uk"
},
"roles": [
"buyer"
],
"details": {
"url": "https://www.nhsbt.nhs.uk/",
"buyerProfile": "https://www.nhsbt.nhs.uk/",
"classifications": [
{
"scheme": "TED_CA_TYPE",
"id": "BODY_PUBLIC",
"description": "Body governed by public law"
},
{
"scheme": "COFOG",
"id": "07",
"description": "Health"
}
]
}
}
],
"buyer": {
"id": "GB-FTS-18293",
"name": "NHS Blood and Transplant"
},
"language": "en"
}